Adrian Woolfson, MD, PhD is a physician-scientist turned serial founder who is co-founder of Genryo, a genome design and writing company, and co-founder of the gene therapy company Replay. Trained in medicine and molecular immunology in the laboratory of Nobel laureate César Milstein, he went on to lead immuno-oncology drug development at Bristol-Myers Squibb and Pfizer, serve as Chief Medical Officer at Nouscom and Head of R&D at Sangamo, and author three bestselling books including On the Future of Species. Adrian believes biology is fundamentally computable, and that the convergence of AI-designed genomes with Genryo’s Sidewinder DNA construction technology will turn biology into the infrastructure of the coming century.

‍

‍

The key takeaways from Adrian's spotlight are:

1. Audacity and vision matter, but deep training is still the foundation
2. Biology is computable, and AI is the only way we will learn to read its language
3. Pick a problem that is tractable within your lifetime